We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Novel ALS Therapy in Human Clinical Trials

News   Jul 17, 2018 | Original Story by Tamara Bhandari for WUSTL

 
Novel ALS Therapy in Human Clinical Trials

Robert Bucelli, MD, PhD, measures Gregory Easter's neuromuscular function. Easter, who has an inherited form of amytrophic lateral sclerosis, a fatal neuromuscular disease, is taking part in a clinical trial to evaluate an experimental drug. New research at Washington University School of Medicine in St. Louis shows the drug extends survival and reverses some neuromuscular damage in mice and rats and may help people whose disease is caused by mutations in the gene SOD1. Credit: Mike Worful, WUSTL.

 
 
 

RELATED ARTICLES

Prenatal Exposure to Violence Leads to Increased Toddler Aggression Toward Mothers

News

“Prenatal violence primarily affects kids via how it affects the mother.”

READ MORE

New Subtype of MS: Neuronal loss but no white matter demyelination

News

researchers have discovered a new subtype of multiple sclerosis (MS), providing a better understanding of the individualized nature of the disease.

READ MORE

Hearing Illusions: McGurk effect decreases with development

News

Research shows there is a developmental shift in sensory dominance as children grow older.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery Neuroscience

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE